Free Trial
NASDAQ:REPL

Replimune Group Q3 2024 Earnings Report

Replimune Group logo
$8.35 -0.41 (-4.68%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$8.65 +0.30 (+3.59%)
As of 05/23/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Replimune Group EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.89
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Replimune Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Replimune Group Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 8, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Replimune Group's Q1 2026 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Replimune Group Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Replimune Group Sees Unusually Large Options Volume (NASDAQ:REPL)
Q4 2025 Replimune Group Inc Earnings Call
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL), a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

View Replimune Group Profile

More Earnings Resources from MarketBeat